Description: Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Home Page: www.bicycletherapeutics.com
BCYC Technical Analysis
Babraham Research Campus
Cambridge,
CB22 3AT
United Kingdom
Phone:
44 1223 261 503
Officers
| Name | Title |
|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | CEO & Exec. Director |
| Mr. Lee H. Kalowski M.B.A., MBA | Pres & CFO |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE | Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer |
| Dr. Christian Heinis | Scientific Founder |
| Mr. Alistair Milnes | Chief Operating Officer |
| Dr. Nicholas Keen Ph.D. | Chief Scientific Officer |
| Mr. David E. Borah CFA | VP of Capital Markets & Investor Relations |
| Mr. Zafar Qadir | Gen. Counsel |
| Dr. Gillian Langford | Head of Clinical and Project Management |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1395 |
| Price-to-Sales TTM: | 61.6912 |
| IPO Date: | 2019-05-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 119 |